Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00473525 · ClinicalTrials.gov registry record · Phase 2
12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 303
- Enrollment target
NCT00473525 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 303 participants.
The verdict
NCT00473525, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 303 participants
- Enrollment target
Study Summary
The purpose of this Phase 2a study is to evaluate the efficacy, safety and tolerability, of multiple parallel doses of PF-00734200 following oral administration to adult human subjects with T2DM who currently are on a stable dose of metformin.
Interventions
- DRUG Placebo
- DRUG PF-00734200 20 mg QD
- DRUG PF-00734200 10 mg QD
- DRUG PF-00734200 5 mg QD
- DRUG PF-00734200 2 mg QD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 303 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00473525
The ClinicalTrials.gov registry entry for NCT00473525 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 303 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00473525 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00473525 about?
NCT00473525 is a clinical study titled "12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin". The purpose of this Phase 2a study is to evaluate the efficacy, safety and tolerability, of multiple parallel doses of PF-00734200 following oral administration to adult human subjects with T2DM who currently are on a stable dose of metformin.
What is the current status of trial NCT00473525?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 303 participants. The study started on 2007-07. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00473525?
The interventions under investigation include: Placebo (DRUG), PF-00734200 20 mg QD (DRUG), PF-00734200 10 mg QD (DRUG), PF-00734200 5 mg QD (DRUG), PF-00734200 2 mg QD (DRUG).
Who is sponsoring clinical trial NCT00473525?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.